两名患者玻璃体内游离贝伐单抗和游离血管内皮生长因子的水平
Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients.
作者信息
Beer Paul M, Wong Susan J, Hammad Amjad M, Falk Naomi S, O'Malley Martin R, Khan Samira
机构信息
Retina Consultants, PLLC, 1220 New Scotland Road, Suite 201, Slingerlands, NY 12159, USA.
出版信息
Retina. 2006 Oct;26(8):871-6. doi: 10.1097/01.iae.0000233327.68433.02.
BACKGROUND
Vitreous levels of unbound bevacizumab (Avastin) and unbound vascular endothelial growth factor (VEGF) were determined in two patients. Patient 1 underwent repair of an 8-day-old rhegmatogenous retinal detachment 4 weeks after a single intravitreal bevacizumab injection, and Patient 2 underwent vitreous biopsy for endophthalmitis 48 hours after a combined bevacizumab and triamcinolone injection.
METHODS
The samples of vitreous fluid were analyzed for unbound bevacizumab and unbound VEGF levels using microsphere immunoassays targeted for bevacizumab and VEGF.
RESULTS
In Patient 1, the unbound bevacizumab level was 0.16% of the loading dose (or 500,000 pg/mL) and the unbound VEGF concentration was <41 pg/mL 4 weeks after the bevacizumab injection. In Patient 2, the unbound bevacizumab level was 53% of the loading dose (or 166,000,000 pg/mL) at 48 hours, with an unbound VEGF level of <41 pg/mL.
CONCLUSION
A single dose of intravitreal bevacizumab is likely to provide complete intravitreal VEGF blockade for a minimum of 4 weeks, with an intravitreal bevacizumab half-life of approximately 3 days.
背景
测定了两名患者玻璃体内游离贝伐单抗（阿瓦斯汀）和游离血管内皮生长因子（VEGF）的水平。患者1在单次玻璃体内注射贝伐单抗4周后，接受了8日龄孔源性视网膜脱离修复术；患者2在联合注射贝伐单抗和曲安奈德48小时后，因眼内炎接受了玻璃体活检。
方法
使用针对贝伐单抗和VEGF的微球免疫测定法分析玻璃体液样本中的游离贝伐单抗和游离VEGF水平。
结果
在患者1中，贝伐单抗注射4周后，游离贝伐单抗水平为负荷剂量的0.16%（或500,000 pg/mL），游离VEGF浓度<41 pg/mL。在患者2中，48小时时游离贝伐单抗水平为负荷剂量的53%（或166,000,000 pg/mL），游离VEGF水平<41 pg/mL。
结论
单次玻璃体内注射贝伐单抗可能至少4周内在玻璃体内提供完全的VEGF阻断，玻璃体内贝伐单抗的半衰期约为3天。
Zotero 插件